Respirology

Top Medical News
Stephen Padilla, 13 hours ago
Initiation of methotrexate appears to lower the risk of infection in patients with sarcoidosis at 6 months as compared to azathioprine, suggest the results from the emulation of a target trial with pre-existing data. However, the favourable effect of methotrexate is attenuated at 9 months.
Roshini Claire Anthony, Yesterday

An increasing intake of unprocessed red meat and processed meat may be tied to an elevated risk of multiple medical conditions, according to a recent prospective study from the UK.

Audrey Abella, Yesterday
Older adults and elderly individuals are still more susceptible to acquiring COVID-19 infection than younger individuals, even if individuals from both age groups stayed in the same household, a Singapore study has shown.
Yesterday
Smokers with consistently low serum vitamin D level are likely to exhibit accelerated decline in lung function, a study has found.
Jairia Dela Cruz, 2 days ago
Inhaled triple therapy containing beclomethasone dipropionate, formoterol fumarate, and glycopyrronium helps improve lung function and symptom control, as well as cut the frequency of exacerbations, in patients with chronic obstructive pulmonary disorder (COPD) treated in a real-world setting, according to data from the TRICOP noninterventional study.
Stephen Padilla, 4 days ago
The Artificial Breathing Capability Device, or ABCD, has been shown to be safe, efficacious, and cost-effective option for respiratory support, according to a study. It can be considered for adults and children when there is a shortage of ventilators especially during the COVID-19 pandemic.
Elvira Manzano, 4 days ago
The anthelmintic agent ivermectin, tested in the EPIC* trial of 476 patients, did not significantly shorten symptom duration in adults with mild COVID-19.
Special Reports
Prof. David Paterson, 30 Mar 2021
Intensive care unit (ICU) patients are at risk of developing serious infections with multidrug-resistant organisms (MDROs), which require appropriate and adequate antibiotic coverage. Early empirical coverage is pivotal in saving patients’ lives. At a recent webinar co-organized by the Society of Infectious Disease (Singapore) and Pfizer, renowned Professor David Paterson, Professor of Medicine and Director, The University of Queensland Centre for Clinical Research, and Consultant Infectious Diseases Physician, Royal Brisbane and Women’s Hospital, Brisbane, Australia, discussed the role of newer antimicrobial agents, including ceftazidime-avibactam (Zavicefta) in the management of MDROs in the ICU. Dr Wong Sin Yew, Infectious Disease Physician at Gleneagles Medical Centre and Mount Elizabeth Novena Specialist Centre, Singapore, chaired the event.
Dr. Asok Kurup, Dr. Kenneth Chan, 07 Dec 2020
The rising incidence of infections caused by multidrug-resistant (MDR) gram-negative bacteria has become a serious health threat and a major challenge for intensivists. Against a backdrop of high patient mortality and risk factors for infection in intensive care units (ICU), early adequate therapy is of paramount importance. At a recent Pfizer-sponsored symposium, Dr Asok Kurup, Infectious Disease Physician, Singapore presented the implications of MDR gram-negative infections in critically ill patients in Asia, while Dr Kenneth Chan, Respiratory Physician and Intensivist, Singapore highlighted the role of ceftazidime-avibactam (Zavicefta) and shared published real-world data on ceftazidime-avibactam. 
Pearl Toh, 26 Nov 2020
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.
01 Nov 2020
As the COVID-19 pandemic continues to spread around the globe, comparison is often drawn to influenza, another contagious respiratory-borne disease. Recently, Dr Azureen Azmel, a consultant infectious disease physician at Hospital Tengku Ampuan Rahimah (HTAR), and Dr Leong Chee Loon, a consultant infectious disease physician with Hospital Kuala Lumpur (HKL), came together to discuss about the importance of annual influenza vaccination during the current COVID-19 pandemic.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Pearl Toh, 16 Sep 2020
Mepolizumab, a first-in-class anti-IL-5* antibody, effectively prevents asthma exacerbations in patients with severe eosinophilic asthma (SEA), according to a presentation at the ERS 2020 Congress.
10 Dec 2019
Oral H1-antihistamines are the initial treatment of choice for allergic rhinitis (AR) and chronic urticaria in the primary care setting. However, in a diverse population of patients with AR and urticaria, primary care physicians are faced with the challenge of prescribing the best therapy amid a wide armamentarium of antihistamines available.
Conference Reports
Roshini Claire Anthony, 12 Apr 2021

Treatment with the human monoclonal antibody tezepelumab reduced exacerbations and improved asthma control, lung function, and quality of life in adults and adolescents with severe, uncontrolled asthma, according to the phase III NAVIGATOR study presented as a poster at AAAAI 2021.

Roshini Claire Anthony, 26 Mar 2021

The use of face masks to reduce transmission of COVID-19 does not appear to affect oxygen saturation levels in individuals with asthma, according to a study presented at AAAAI 2021.

Pearl Toh, 19 Mar 2021
Dupilumab effectively prevents severe asthma exacerbations and improves lung function in patients with difficult-to-treat type 2 asthma, according to a post hoc analysis of the LIBERTY ASTHMA QUEST study presented at AAAAI 2021.
Roshini Claire Anthony, 18 Mar 2021

Patients with asthma reliant on oral corticosteroids (OCS) may be able to gradually cease or reduce their OCS dose after initiating treatment with benralizumab, according to results of the phase IIIb PONENTE* trial.

Pearl Toh, 14 Mar 2021
The interleukin-5 (IL-5) inhibitor mepolizumab reduces asthma exacerbations in patients with severe asthma across a broad range of baseline clinical characteristics and regardless of comorbidities, according to studies presented at the 2021 AAAAI Meeting.
Natalia Reoutova, 26 Jan 2021

Mild cases are estimated to comprise over half of the overall asthma population. Unlike in most other chronic conditions, patients with mild asthma are still at risk of serious outcomes, including death, according to Professor Helen Reddel of the Woolcock Institute of Medical Research, University of Sydney, who spoke at the Advances in Medicine 2020 virtual conference. [Eur Respir J 2007;30:403-406; Can Respir J 2010;17:74-80; Royal College of Physicians. Why asthma still kills: National Review of Asthma Deaths Confidential Enquiry Report. London, 2014]

Natalia Reoutova, 26 Jan 2021

Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease that is not well understood. Therapy for COPD is often started late, while triple therapy or inhaled corticosteroid (ICS)-containing regimens are used inappropriately in some patients.

CME Modules
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download